Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharm Sci ; 71: 99-111, 2015 Apr 25.
Article in English | MEDLINE | ID: mdl-25708940

ABSTRACT

PURPOSE: To engineer a hybrid nanocarrier system based on lipid and polymer for the nasal delivery of tenofovir disoproxil fumarate (TDF), and further to investigate its physicochemical, molecular, microstructural, and stability aspects. METHODS: Nanoparticles were prepared by melt emulsification-probe sonication technique. A 3(2) factorial design was used to identify key formulation variables influencing the characteristics of drug-loaded carrier. FT-IR, mass spectroscopy (MS) and (1)H NMR was used to probe molecular interactions among the components of the system, while the surface morphology was imagined through electron microscopy (TEM and SEM). Thermal analysis and powder X-ray diffraction (PXRD) was used to explore melting and crystallization behavior of drug and the carrier lipid. PLN-9 GEL was studied for its rheology, drug release, ex-vivo permeation, histopathology, and stability. RESULTS: Batch PLN-9 had size of 239 nm, drug encapsulation of 87.14% and revealed spherical morphology. MS, FT-IR and (1)H NMR established compatibility between the drug (TDF) and the carrier lipid (Lauric acid), while, a strong H-bonding was identified between the amino (-NH2) group of drug and the carboxyl (-COOH) group of pemulen polymer. Thermal analysis confirmed an amorphous TDF within the carrier matrix. PXRD analysis indicated substantial change in the molecular packing and subcell structure of carrier lipid during the PLN processing. PLN-9 GEL had shear thinning rheology, an anomalous type (n>0.5) of drug release and possessed potential to transport TDF across the nasal mucosa with an average flux of 135.36 µg/cm(2)/h. CONCLUSION: The designed carrier can encapsulate TDF and accentuates its transnasal flux, thus could be used as a carrier for an effective nasal delivery of TDF.


Subject(s)
Anti-HIV Agents , Drug Carriers , Nanoparticles , Reverse Transcriptase Inhibitors , Tenofovir , Administration, Intranasal , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/chemistry , Calorimetry, Differential Scanning , Drug Carriers/administration & dosage , Drug Carriers/chemistry , Drug Liberation , Drug Stability , Lipids/chemistry , Magnetic Resonance Spectroscopy , Mass Spectrometry , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Nasal Mucosa/anatomy & histology , Nasal Mucosa/drug effects , Nasal Mucosa/metabolism , Polymers/chemistry , Powder Diffraction , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/chemistry , Rheology , Spectroscopy, Fourier Transform Infrared , Tenofovir/administration & dosage , Tenofovir/chemistry , X-Ray Diffraction
SELECTION OF CITATIONS
SEARCH DETAIL
...